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Abstract 
 
Background and aims: Carvedilol, a non-selective beta-blocker (NSBB) with additional anti-
alpha 1 receptor activity, is a potent portal hypotensive agent. It has been used as prophylaxis 
against variceal bleed. However, its safety in decompensated liver cirrhosis with ascites is still 
disputed. In this study, we examined whether long-term use of carvedilol in the presence of ascites 
is a risk factor for mortality.  
 
Methods: This was a single-centre retrospective analysis of 325 consecutive patients with liver 
cirrhosis and ascites presenting to our Liver Unit between 1st of January 2009 to 31st August 2012. 
The primary outcome was all-cause and liver-specific mortality in patients receiving or not 
receiving carvedilol as prophylaxis against variceal bleeding. 
 
Results: The final cohort after propensity score matching comprised 264 patients. Baseline ascites 
severity and UK End Stage Liver Disease (UKELD) score between carvedilol (n=132) and non-
carvedilol (n=132) groups were comparable. Median follow-up time was 2.3 years. Survival at the 
end of the follow-up was 24% and 2% for carvedilol and non-carvedilol group respectively (Log 
Rank p<0.0001). The long-term survival was significantly better in carvedilol than non-carvedilol 
group (Log Rank p<0.001). The survival difference remained significant after adjusting for age, 
gender, ascites severity, aetiology of cirrhosis, previous variceal bleed, spontaneous bacterial 
peritonitis prophylaxis, serum albumin and UKELD with hazard ratio of 0.59 [CI 0.44, 0.80] 
(p=0.001), suggesting 41% reduction in mortality risk. When stratified as per the severity of ascites, 
carvedilol therapy resulted in hazard ratio of 0.47 [0.29, 0.77] (p=0.003) in those with mild ascites. 
Even with moderate or severe ascites, carvedilol use was not associated with increased mortality 
risk. 
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Conclusion: Long-term carvedilol therapy is not harmful in decompensated cirrhosis with ascites. 
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Graphical abstract 
 
Lay summary:  
The safety of carvedilol and other non-selective beta blocker in liver cirrhosis with ascites is still 
debated. In this study, we have shown that carvedilol therapy in patients with liver cirrhosis and 
ascites was associated with reduced risk of mortality, particularly in those with mild ascites. We 
concluded that low dose, chronic treatment with carvedilol in patients with liver cirrhosis and 
ascites is not detrimental.  
 
Abbreviations: 
NSBB, non-selective beta-blocker; ALD, Alcoholic liver disease; NAFLD, Non-alcoholic fatty 
liver disease; HCC, Hepatocellular carcinoma; SBP, Spontaneous bacterial peritonitis; PSM, 
Propensity score matching; PT, Prothrombin time; INR, International Normalised Ratio; 
UKELD, United Kingdom Model for End Stage Liver Disease; MELD, Model for End Stage 
Liver Disease. 
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INTRODUCTION 
 
Liver cirrhosis remains a leading cause of death worldwide. In the United Kingdom alone mortality 
from liver cirrhosis has risen dramatically in the last decade tandem with the rise in alcohol 
consumption and the epidemic of obesity [1]. Portal hypertension underlies many of its fatal 
complications. For this reason, non-selective beta-blocker (NSBB) was proposed to be beneficial 
in the management of patients with varices. Its unselective beta-blockade reduces cardiac output 
and splanchnic blood flow while the unopposed effect of alpha 1 receptors leads to splanchnic 
vasoconstriction thus reducing portal pressure and its attendant complications [2, 3]. Indeed, 
NSBB therapy has been associated with a 40% reduction in the risk of variceal bleeding and in 
combination with endoscopic ligation, the risk of rebleeding was lower than that seen with either 
therapy alone [4].  
 
Lowering of portal pressure with NSBB therapy has also been shown to reduce the development 
of ascites, refractory ascites and hepatorenal syndrome [5]. Furthermore, the effect of NSBB on 
intestinal permeability, bacterial translocation and inflammatory response has been proposed to 
mitigate the risk of developing spontaneous bacterial peritonitis [6, 7]. Mookerjee et al have 
demonstrated an association between short-term survival with NSBB therapy and a significant 
reduction in inflammatory markers [7]. Its benefit on survival was further supported by the finding 
of higher in-hospital mortality among those with decompensated cirrhosis without NSBB 
compared with those who received NSBB irrespective of the ascites severity [8]. 
 
Carvedilol, an NSBB with intrinsic anti-alpha 1 receptor activity, has been associated with a greater 
reduction in portal pressure than the traditional beta blocker, propranolol [9]. In a meta-analysis, 
the proportion of patients achieving target haemodynamic response was higher with carvedilol 
than propranolol [9]. Additionally, the use of carvedilol has been shown to reduce portal pressure 
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in those who initially failed to respond to propranolol. Its action on alpha 1 receptor reduces 
portocollateral resistance, and its effects on hepatic stellate cells diminished intrahepatic resistance 
[10]. In a rodent model of liver injury, carvedilol has been reported to mitigate the development 
of fibrosis by modulating inflammatory cytokines and enhancing antioxidant response [11].  
 
However, the safety of carvedilol and other NSBB in cirrhosis with ascites is still debated. Sersté 
et al reported poor survival among patients with refractory ascites on NSBB therapy [12]. 
Additionally, NSBB therapy has been associated with increased risk of paracentesis induced 
circulatory dysfunction [12, 13]. A potential mechanism underlying these observations is that 
NSBB can reduce cardiac output and perfusion, especially renal blood flow. In a milieu 
characterised by hemodynamic derangement associated with cirrhosis, such effect can potentially 
compromise organ perfusion leading to a multitude of complications including hepatorenal 
syndrome [14]. This led to the ‘therapeutic window hypothesis’ which posits that the development 
of refractory ascites marks the point at which beta-blockade has a detrimental effect on cardiac 
function and mean arterial pressure [15].  
 
In clinical practice, this debate has led to uncertainty surrounding the role of NSBB and carvedilol 
in decompensated cirrhosis with ascites [16]. From a practical standpoint, the main question is 
whether carvedilol should be continued once ascites developed and progressed. We have 
previously shown that carvedilol at a low dose of 12.5 mg for four weeks is well tolerated and 
significantly reduced portal pressure without compromising systemic haemodynamics [3, 17]. In 
the present study, we sought to examine whether long-term use of carvedilol (therapy of more 
than four weeks) in the presence of ascites is a risk factor for mortality. 
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PATIENTS AND METHODS 
 
Study population 
This retrospective analysis included consecutive patients with cirrhosis and ascites who were 
admitted to the Liver Unit at The Royal Infirmary of Edinburgh between the 1st of January 2009 
to the 31st of August 2012. The Royal Infirmary of Edinburgh serves as a tertiary referral centre 
for Lothian as well as a local hospital for Edinburgh city (population ~800,000).	 In our unit, 
carvedilol is the NSBB of choice for primary prophylaxis for oesophageal variceal haemorrhage 
(grade II or above on endoscopy) [18-21] and secondary prophylaxis if endoscopic band ligation 
is not tolerated or preferred by patient. Carvedilol is commenced at a low dose of 6.25 mg once 
daily and if tolerated, it is titrated to a target dose of 12.5 mg daily.  
 
Patients were identified from a prospectively collected database. Date of the first radiologically 
confirmed ascites was taken as the time of entry into the study. The use of carvedilol was 
ascertained by history and medicine reconciliation obtained from electronic patient record 
(TrakCare, InterSystems Corp, MA, USA). Exclusion criteria were: non-liver causes of ascites, the 
use of selective beta-blocker (e.g. atenolol, bisoprolol) or other non-selective beta-blocker (e.g. 
propranolol), carvedilol therapy of less than four weeks and those who underwent liver 
transplantation (Figure 1). If carvedilol was discontinued during the study period, they remained 
in the carvedilol group as the chronic duration of the carvedilol treatment might have an impact 
on the long-term outcome. 
 
Outcomes and follow-up 
Primary outcomes measured were: all-cause mortality and liver-related mortality. All cases were 
followed up from the date of index presentation until the date of death or the 31st December 2015 
whichever was earlier.  
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Data extraction 
Demographic and imaging data were obtained from electronic integrated clinical records system 
(TrakCare, InterSystems Corp, MA, USA). The Information Services Division (ISD), NHS 
Scotland provided data linkage to the national dataset on mortality (National Records Scotland). 
The following variables were recorded: age, gender, aetiology of liver disease, previous variceal 
bleed, severity of ascites, laboratory data (serum creatinine, sodium, bilirubin, albumin, 
prothrombin time and international normalised ratio (INR)) and the use of antibiotics for primary 
or secondary spontaneous bacterial peritonitis (SBP) prophylaxis [20, 22]. Laboratory variables 
recorded were those obtained at the time of entry to the study. Severity of ascites was classified as 
mild, moderate or severe as documented in the radiology report.  
 
Severity of liver disease was assessed using the UK model for End-stage Liver Disease (UKELD), 
which predicts annual mortality [23]. Given the retrospective nature of this analysis, Child-
Turcotte-Pugh score was not included as the presence and the degree of hepatic encephalopathy 
was not reliably recorded. Model for End-Stage Liver Disease (MELD) was also calculated and 
compared between the groups, however, as carvedilol use of less than four weeks was excluded, 
the impact is somewhat biased.  
 
Ethical approval 
This study was considered as a retrospective review by the local committee in our institution hence 
no formal ethical approval from the NHS Research Ethics Committee was necessary. However, 
this study received approval from the Caldicott Guardian of NHS Lothian and the Caldicott 
Guardian of ISD for NHS Scotland.  
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Statistical analysis 
Statistical analyses were performed using IBM SPSS Statistics for Macintosh, Version 21.0. (IBM 
Corp., Armonk, NY, USA), except for propensity score matching (PSM) analyses, which were 
performed on R, version 3.3.2 (The R Foundation for Statistical Computing, Vienna, Austria). The 
approach of Tukey’s boxplot was followed to detect outliers with values outside the whiskers (2.2  
times the interquartile range) being considered as outliers [24]. Outliers were checked and 
corrected if needed or retained where appropriate. Data were presented as mean (SD) for 
continuous variables and as frequencies and percentages for categorical variables. Kaplan-Meier 
survival analysis was used to calculate the cumulative incidence of primary outcomes. Cox 
regression models were fitted to adjust for effects of baseline characteristics and to determine their 
significance as a predictor for each outcome. Covariates with p≤0.200 in univariate regression 
analysis were included simultaneously in the multivariate models. The risk of the outcomes was 
presented as hazard ratio (95% confidence intervals). An unadjusted hazard ratio (HR) indicates 
an association between mortality and a single predictor. An adjusted HR indicates relationship 
between mortality and a predictor after adjusting for other independent variables. The 
proportional hazard assumptions were determined using log minus log plots for each variable. A 
p-value of less than 0.05 was deemed significant. To minimise the probability of selection bias, 
statistical analyses were performed in a cohort of carvedilol and non-carvedilol matched using the 
propensity score matching (PSM).  The propensity score matching is a subject's probability of 
treatment, conditional on observed baseline covariates [25]. PSM is a recognised method of 
controlling for selection bias [26]. A PSM for carvedilol use versus non-carvedilol use was 
generated by multiple logistic regression. This model included all variables with clinical relevance 
to mortality (age, gender, aetiology, previous variceal bleed, severity of ascites, SBP antibiotic 
prophylaxis, serum sodium, serum creatinine, serum albumin, total bilirubin, International 
Normalised Ratio, and UK End Stage Liver Disease). The nearest available matching (1:1) on the 
estimated PSM method was used to construct the control group. Balance was achieved after 
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matching between the carvedilol (n=132) and non-carvedilol (n=132) groups on the selected 
confounders (Supplementary Data Table 1). The propensity score matching was performed using 
the MatchIt package in R [27, 28]. 
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RESULTS 
 
Clinical characteristics 
Mean age for the entire cohort was 59.5 (SD 12.3) years and 67% were men. A total of 132 patients 
were on carvedilol with a median dose of 12.5 mg (range 6.25 -12.5 mg) per day. The 
discontinuation rate for carvedilol was 9% (12/132) in the first year and 80.3% (106/132) 
continued carvedilol therapy until the end of follow-up period.  Mean UKELD and MELD score 
were 56 (SD 6.2) and 13.9 (SD 6.1) respectively. The prevalence of mild, moderate and severe 
ascites was 43.3%, 32.2% and 23.5% respectively. Baseline characteristics of the study population 
following the PSM are outlined in Table 1. The two groups were comparable with regards to 
aetiology of liver disease (p=0.91), previous variceal bleed (p=0.79), severity of ascites (p=0.93), 
antibiotic for SBP prophylaxis (p=0.41), serum sodium (p=0.41), serum creatinine (p=0.45), serum 
albumin (p=0.51), serum total bilirubin (p=0.71), INR (p=0.47), UKELD score (p=0.33) and 
MELD score (p=0.24).   
  
Survival       
The 264 patients were followed up for a median of 2.2 (IQR 0.8-4.1) years, during which there 
were 191 (72.3%) deaths. Among those on carvedilol, the estimated six-month and two-year 
survival was 95% and 61% respectively (Table 2). For non-carvedilol group, six-month survival 
was 89%, which declined to 47% at two-years. Similarly, survival at the end of the follow-up period 
was 24% for patients on carvedilol compared with only 2% among those who did not receive 
carvedilol (p=0.001). Median survival time was 1230 [CI 1006.9, 1453.1] days and 713 [CI 484.9, 
941.0] days for carvedilol and non-carvedilol group respectively. After the first year, the unadjusted 
survival advantage associated with carvedilol was between 10 to 15% per year (Table 2). 
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As shown in Kaplan-Meier curves (Figure 2), the unadjusted hazard for carvedilol group was 
significantly lower than that seen in non-carvedilol group (Log Rank p=0.001). The use of 
carvedilol resulted in an unadjusted hazard ratio of 0.61 [CI 0.46, 0.81], when compared with those 
without carvedilol. The survival difference remained significant after adjusting for age, gender, 
previous variceal bleed, severity of ascites, aetiology of cirrhosis, SBP prophylaxis, serum albumin 
and UKELD with hazard ratio of 0.59 [CI 0.44, 0.80] suggesting 41% reduction of mortality risk 
associated with its use.  
 
Ascites severity modifies the effect of carvedilol 
Among those with mild ascites, the use of carvedilol resulted in an unadjusted hazard ratio of 0.51 
[CI 0.33, 0.79]. The relationship remained significant even after adjusting for age, gender, aetiology 
of cirrhosis, previous variceal bleed, SBP prophylaxis, serum albumin and UKELD with 43% 
reduction in risk of death with carvedilol (HR 0.47 [CI 0.29, 0.77], p=0.003) when compared with 
those not on carvedilol. In moderate ascites, the trend of decreased risk of death with carvedilol 
was not statistically significant (p=0.08) with adjusted HR 0.61 [0.36, 1.06]. Similarly, we did not 
observe significant difference in the risk of death between carvedilol and non-carvedilol group 
among those with severe ascites (HR 0.77 [CI 0.42, 1.43], p=0.41) (Table 3). 
 
Predictors of mortality  
Table 4 demonstrates the findings from univariate and multivariate analyses. In univariate analysis, 
the following variables; carvedilol use, age, NAFLD as aetiology of liver cirrhosis, SBP prophylaxis 
were significantly associated with death. However, the effect of age was rendered insignificant after 
adjusting for other variables in a multivariate analysis (Table 4). In contrast, the association 
between nonalcoholic fatty liver disease and death remained significant with a two-fold increase in 
mortality when compared with alcoholic liver disease (HR 2.25 [CI 1.32, 3.84]). Additionally, 
antibiotic use for SBP prophylaxis was an independent predictor of mortality (p=0.007).  
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Causes of death 
There were 191 deaths in the entire cohort (72.3%; 191/264). Of these 90.6% (173/191) were 
liver-related deaths. The leading cause of liver-related death was alcoholic liver disease (ALD) 
(53.9%; 103/191) followed by variceal bleed (14.1%; 27/191), hepatocellular carcinoma (HCC) 
(10.5%; 20/191) and Non-alcoholic fatty liver disease (NAFLD) (9.4%; 18/191). 
 
ALD related deaths for carvedilol and non-carvedilol group were 48.2% (40/83) and 41.7% 
(43/108) respectively (p=0.66). The proportion of deaths relating to variceal bleed (16.9%; 14/83) 
for carvedilol and (12%; 13/108) for non-carvedilol group (p=0.40). Of the 14 patients who died 
of variceal haemorrhage, eight were on 12.5 mg of carvedilol and the remaining were on 6.25 mg 
of carvedilol. Similarly, there was no difference in HCC, NAFLD, viral and sepsis related deaths 
between the two groups (Table 5). 
 
The leading cause of non-liver related deaths was cardiovascular disorders (18.8%; 36/191). 
Cardiovascular related deaths occurred in 16.9% (14/83) of patients on carvedilol and in 20.4% 
(22/108) of those in non-carvedilol group (p=0.58). We did not observe significant difference in 
cardiovascular-related death between patients with NAFLD on carvedilol and those with NAFLD 
without carvedilol. Similarly, there was no difference in deaths relating to extrahepatic malignancy, 
respiratory or renal disorders between the carvedilol and non-carvedilol groups (Table 5).  
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DISCUSSION 
 
In this study, we examined for the first time whether long-term, low dose carvedilol therapy 
influences mortality in established cirrhosis with ascites. It also addressed an important clinical 
question-should carvedilol be continued in the presence of ascites. Our data highlight two 
important points. First, we have shown that long-term use of low dose carvedilol in cirrhosis with 
ascites was associated with reduced risk of mortality. Second, this association was modified by the 
severity of ascites; carvedilol therapy was associated with decreased risk of death in mild ascites 
but did not affect the outcome of those with moderate or severe ascites. Importantly, even in the 
presence of severe ascites, carvedilol therapy was not associated with excess mortality.  
 
Our findings are in agreement with previous studies which largely focused on the role of 
propranolol in cirrhosis. The use of NSBB in cirrhosis with ascites has been associated with 
improved survival in various population ranging from hospital admission [8] to those on transplant 
waiting list [29]. Our study exclusively examined the impact of carvedilol in the presence of ascites. 
Carvedilol is the NSBB of choice in the preventative strategy against variceal bleed in our centre. 
Its safety in decompensated cirrhosis with ascites is still debated, for instance, its use in two of the 
studies examined in a recent meta-analysis was associated with increased mortality [30].  
 
It was postulated that the vasodilatory effect from the concomitant alpha-blockade can potentially 
exacerbate arterial hypotension in the already precarious haemodynamic state. The effects of 
carvedilol on systemic haemodynamics are dose dependent [3, 17] and we have previously shown 
that carvedilol at 12.5 mg for four weeks led to a marked reduction in portal pressure without 
significantly altering the mean arterial pressure [3]. In the present study, carvedilol therapy at a 
median dose of 12.5 mg per day for a median duration of 49 months was associated with reduced 
risk of death. The estimated survival throughout the follow-up period was favourable with 
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carvedilol. Indeed, the survival at one-year was 78% for carvedilol and 65% for non-carvedilol 
despite the similarities in the baseline UKELD score. These groups were also similar with regards 
to liver disease severity, aetiology of liver disease and the degree of ascites.  
The disparities between our findings and that of Njei et al may also have been attributed to the 
differences in population studied [30]. Specifically, our study population comprised all grades of 
ascites rather than solely focused on refractory ascites. Our data suggest that the severity of ascites 
modifies the effect of carvedilol. The use of carvedilol in mild ascites was associated with 53% 
reduced risk of long-term mortality. Although the risk of death in moderate and severe ascites was 
statistically similar between carvedilol and non-carvedilol group, the trend was that the impact of 
carvedilol decreased with increasing severity of ascites. This is consistent with the ‘therapeutic 
window hypothesis’ which stipulates that NSBB therapy may be effective only within a particular 
clinical window of advanced liver disease [15].  
 
The underlying mechanisms for the protective effect of carvedilol in our study is unclear. It is 
plausible that similar to the traditional NSBB, the benefits incurred hinge on its portal hypotensive 
effect. Despite the similarities in variceal bleed related mortality between the two groups, the long-
term effects of its portal pressure lowering on ascites related complications, bacterial translocation, 
anti-inflammatory and anti-fibrotic cannot be excluded [7, 11]. The cause of death documented 
reflects the progression of the underlying liver disease compounded by concurrent comorbidities, 
in particular, ischaemic heart disease.  
 
Some limitations must be acknowledged. First, the retrospective nature of this study precludes the 
analysis of spontaneous bacterial peritonitis, evidence of autonomic dysfunction, interaction of 
concomitant drugs, blood pressure measurements, hepatic encephalopathy, ongoing alcohol 
consumption and compliance with carvedilol. Second, degree of ascites severity was based on 
radiology reports, which was subject to operator bias. Additionally, we did not have a reliable 
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information on the clinical course of ascites following the treatment with carvedilol. Similarly, we 
do not have reliable data regarding the safety of carvedilol in patients with refractory ascites. 
Information regarding concomitant use of diuretics and paracentesis were also not available.  
 
However, our cohort represents real-world insight of patients with established cirrhosis and 
ascites. We used propensity score matching to minimise any potential bias. Our data have 
important implications for clinical management of patients with established cirrhosis and ascites. 
Long-term treatment with carvedilol at a low dose, even in the presence of severe ascites, is not 
associated with increased mortality. Therefore, our data support continuing carvedilol therapy in 
patients with ascites unless there are features to suggest significant haemodynamic perturbation 
compromising organ perfusion. As such, prospective randomised controlled trial is required to 
evaluate the efficacy of carvedilol in well characterised spectrum of cirrhosis and ascites. Further 
studies on the effects of carvedilol on the underlying disease progression and systemic 
inflammatory response modulation might unravel its effect on long-term survival. 
 
In conclusion, we have demonstrated that low dose, chronic treatment with carvedilol in patients 
with decompensated cirrhosis and ascites is not detrimental. Furthermore, we have shown that 
carvedilol therapy in this setting was associated with reduced mortality, particularly in those with 
mild ascites. Our data support the need of prospective studies to determine its impact in severe 
and refractory ascites.  
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Table 1 
 
 
 
 
Clinical characteristics 
 
 
Pre-match 
 
 
 
 
 
p-value 
 
 
Post-match 
 
 
 
 
 
p-value 
Carvedilol 
group 
(n=132) 
 
Non-
carvedilol 
group 
(n=193) 
 
Carvedilol 
group 
(n=132) 
 
Non- 
carvedilol 
group 
(n=132) 
 
Age (years) 59.1 (12.7) 59.9 (12.0) 0.55 59.1 (12.7) 59.8 (11.9) 0.62 
Men 87 (65.9) 116 (60.1) 0.29 87 (65.9) 89 (67.4) 0.89 
Aetiology 
 
ALD 
NAFLD 
Viral 
Others 
HCC 
 
 
 94 (71.2) 
 15 (11.4) 
  5 (3.8) 
  12 (9.1) 
  6 (4.5) 
 
 
 
157 (81.3) 
15 (7.8) 
   4 (2.1) 
12 (6.2) 
   5 (2.6) 
 
0.31 
 
 
 
 
 
 
 
 
 
94 (71.2) 
15 (11.4) 
5 (3.8) 
12 (9.1) 
6 (4.5) 
 
 
 
101 (76.5) 
12 (9.1) 
4 (3.0) 
10 (7.6) 
5 (3.8) 
 
0.91 
 
 
 
 
 
 
 
Previous variceal bleed 42 (31.8) 66 (34.2) 0.72 42 (31.8) 45 (34.1) 0.79 
Severity of ascites   0.13   0.93 
Mild 
Moderate 
Severe 
 
60 (45.5) 67 (34.7)  60 (45.5) 57 (43.2)  
42 (31.8) 69 (35.8)  42 (31.8) 43 (32.6)  
30 (22.7) 57 (29.5)  30 (22.7) 32 (24.2)  
Antibiotic for SBP 
prophylaxis 
40 (30.3) 34 (17.6) 0.01* 40 (30.3) 33 (25.0) 0.41 
Serum sodium (mmol/L) 134.8 (5.1) 134.6 (5.2) 0.81 134.8 (5.1) 134.3 (5.5) 0.41 
Serum creatinine 
(mmol/L) 
71.8 (31.2) 77.5 (51.1) 0.26 71.3 (26.2) 74.3 (37.8) 0.45 
Serum albumin (g/L) 28.6 (7.8) 28.0 (6.9) 0.48 28.1 (5.6) 27.6 (6.9) 0.51 
Total bilirubin (mmol/L) 87.8 (107.1) 88.4 (106.2) 0.96 88.3 (108.3) 93.2 (104.3) 0.71 
INR 1.5 (0.5) 1.5 (0.5) 0.55 1.5 (0.4) 1.6 (0.5) 0.47 
UKELD 55.7 (6.1) 55.9 (6.1) 0.76 55.7 (6.2) 56.5 (6.3) 0.33 
MELD 12 (9) 13 (9) 0.26 13 (6) 14 (6) 0.24 
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Table 2 
 
 
 
 
Time interval 
 
Estimated survival in percentage 
 
Carvedilol 
 
 
Non-carvedilol 
30-day 98 95 
6 month 95 89 
1-year 78 65 
2-year 61 47 
3-year 55 40 
4-year 39 27 
5-year 33 20  
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Table 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Severity of ascites Carvedilol Non-carvedilol p-value 
Mild 
       Mortality (n, %) 
       Unadjusted HR 
       Adjusted HR 
 
35 (58.3) 
0.51 (0.33 – 0.79) 
0.47 (0.29 – 0.77) 
 
50 (87.7) 
Ref 
Ref 
 
0.000* 
0.003* 
0.003* 
Moderate 
       Mortality (n, %) 
       Unadjusted HR 
       Adjusted HR 
 
26 (61.9) 
0.59 (0.35 – 0.99) 
0.61 (0.36 – 1.06) 
 
34 (79.1) 
Ref 
Ref 
 
0.09 
0.05* 
0.08 
Severe 
       Mortality (n, %) 
       Unadjusted HR 
       Adjusted HR 
 
22 (73.3) 
0.90 (0.50 – 1.61) 
0.77 (0.42 – 1.43) 
 
24 (75.0) 
Ref 
Ref 
 
1.00 
0.73 
0.41 
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Table 4 
 
 
 
                                       Univariate analysis                                      Multivariate analysis 
 
Variables 
Hazard ratio 
(95% confidence interval) 
 
p-value 
Adjusted hazard ratio 
(95% confidence interval) 
 
Adjusted p-value 
Carvedilol 0.61 (0.46 – 0.81) 0.001* 0.59 (0.44 – 0.80) 0.001* 
Age 1.01 (1.00-1.02) 0.04* 1.00 (0.99 – 1.02) 0.34 
Men 1.09 (0.81 – 1.48) 0.55 1.06 (0.77 – 1.47) 0.69 
Aetiology 
ALD 
NAFLD 
HCC 
Viral 
Others 
Previous variceal bleed 
 
Ref 
1.82 (1.18 – 2.81) 
0.44 (0.14 – 1.39) 
0.91 (0.52 – 1.59) 
1.85 (0.90 – 3.78) 
0.80 (0.52 – 1.09) 
 
 
0.007 * 
0.16 
0.75 
0.09 
0.16 
 
Ref 
2.25 (1.32 – 3.84) 
0.51 (0.16 – 1.64) 
1.14 (0.63 – 2.07) 
1.87 (0.89 – 3.94) 
0.77 (0.56 – 1.06) 
 
 
0.003* 
0.26 
0.65 
0.09 
0.11 
Severity of ascites 
Mild 
Moderate 
Severe 
 
Ref 
1.06 (0.76 – 1.48) 
1.20 (0.84 – 1.72) 
 
 
0.71 
0.31 
 
Ref 
0.93 (0.65 – 1.33) 
1.26 (0.87 – 1.84) 
 
 
0.66 
0.22 
SBP prophylaxis 0.64 (0.45- 0.89) 0.009* 0.62 (0.43 – 0.88) 0.007* 
Serum sodium 1.01 (0.98 – 1.04) 0.37   
Serum creatinine  1.00 (0.99 – 1.00) 0.88   
Serum albumin 0.98 (0.95 – 1.00) 0.063 0.98 (0.95 – 1.00) 0.09 
Total bilirubin 1.00 (0.99 – 1.00) 0.67   
INR 1.09 (0.81 – 1.45) 0.57   
UKELD 
MELD 
1.00 (0.98 – 1.02) 
1.00 (0.97 – 1.32) 
0.93 
0.44 
0.46 (1.01 – 0.98) 0.46 
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Table 5 
 
 
 
Cause of death 
 
 
Carvedilol 
(n=83) 
n (%) 
 
Non-carvedilol 
(n=108) 
n (%) 
 
p value 
Liver related 
            ALD 
Variceal bleeding 
Sepsis 
NAFLD 
HCC 
Viral 
Others 
 
43 (51.8) 
14 (16.9) 
12 (14.5) 
7 (8.4) 
11 (13.3) 
9 (10.8) 
29 (34.9) 
 
60 (55.6) 
13 (12.0) 
20 (18.5) 
11 (10.2) 
9 (8.3) 
9 (8.3) 
28 (25.9) 
 
0.66 
0.40 
0.56 
0.80 
0.34 
0.62 
0.20 
Non-liver related 
Vascular event 
Respiratory 
Renal 
            Extra-hepatic malignancy 
 
14 (16.9) 
12 (14.5) 
5 (6.0) 
6 (7.2) 
 
22 (20.4) 
19 (17.6) 
6 (5.6) 
8 (7.4) 
 
0.58 
0.69 
1.00 
1.00 
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Figure 1 
  
	
 
 
 
 
 
 
 
 
 
 
 
 
Liver disease patients screened from
discharge sumamries
1st January 2009 - 31st August 2012
(n=1671 discharges)
Only index admission 
included 
Non-carvedilol 
group (n=193)
Non-carvedilol
group (n=132)
Patients on 
NSBB (n=168)
Carvedilol
group (n=132)
Carvedilol 
group (n=132)
Excluded
Carvedilol use < 4weeks (n=10), 
Propranolol (n=16) and
Liver transplantation (n=10)
Patients without 
ascites excluded (n=567)
Excluded 
Liver transplantation 
(n=12)
Recurrent admissions 
excluded (n=731)
Propensity score matching
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Figure 2 
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Figure and Table Legends 
	
	
Table 1: Baseline characteristics of study population. Data presented as mean and standard 
deviation (SD) or frequency (n) and percentage where appropriate. *p<0.05 is significant. ALD, 
Alcoholic liver disease; NAFLD, Non-alcoholic fatty liver disease; Viral, Viral hepatitis; HCC, 
Hepatocellular carcinoma; SBP, Spontaneous bacterial peritonitis; PT, Prothrombin time; INR, 
International Normalised Ratio; UKELD, United Kingdom Model for End Stage Liver Disease. 
	
	
Table 2: Estimated survival over time.  
 
	
Table 3: Risk of mortality stratified by the severity of ascites. Adjusted hazard ratio is 
obtained from Cox-regression analysis adjusted to the following variables (carvedilol, age, gender, 
aetiology, severity of ascites, previous variceal bleed, SBP prophylaxis, serum albumin and 
UKELD); Data presented as frequency (n) and percentage of each study group or hazard ratio 
(HR) and 95% confidence interval. *p <0.05 is significant; Ref, reference group. SBP, Spontaneous 
bacterial peritonitis; UKELD, United Kingdom Model for End Stage Liver Disease.  
 
 
Table 4: Independent predictors of mortality across study population. Unadjusted and 
adjusted hazard ratios are obtained from univariate and multivariate analysis respectively. The 
following variables were considered in multivariate analysis (carvedilol, age, gender, aetiology, 
severity of ascites, previous variceal bleed, SBP prophylaxis, serum albumin and UKELD); Data 
presented as hazard ratio (HR) and 95% confidence interval. *p <0.05 is significant; Ref, reference 
group. SBP, Spontaneous bacterial peritonitis; UKELD, United Kingdom Model for End Stage 
Liver Disease. 
 
 
Table 5: Cause of death. Data presented as frequency (n) and percentage of each study group. 
ALD, Alcoholic liver disease; NAFLD, Non-alcoholic fatty liver disease; Viral, Viral hepatitis; 
HCC, Hepatocellular carcinoma. *p <0.05 is significant. 
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Figure 1:	Study flow.	
	
 
 
Figure 2: Kaplan-Meier curves for carvedilol and non-carvedilol groups. Carvedilol therapy 
was associated with lower hazard compared with non-carvedilol group over the follow-up period. 
Log Rank (Mantel-Cox) p value of 0.001; *p<0.05 is significant.  
